Clinical Effect Of Mineralocorticoid Receptor Antagonist Combined With Angiotensin Receptor Blocker Or Angiotensin Converting Enzyme Inhibitor In Treating Diabetic Nephropathy: A Systematic Review And Meta-Analysis
Yaoyao Li,Bin Xu,Lei He,Mengsi Li,Tianya Zhao,Xiaoyan Wu,Ping Gao
2018-01-01
Abstract:Objective: To systematically assess the efficacy and safety of combined therapy with a mineralocorticoid receptor antagonist (MRA) and an angiotensin receptor blocker (ARB) or angiotensin converting enzyme inhibitor (ACEI) for patients with diabetic nephropathy (DN). Methods: PubMed, MEDLINE, Cochrane Library, Embase and EBSCO were electronically searched to collect randomized controlled trails of the combined therapy of MRA and ARB/ACEI versus ARB/ACEI alone for DN patients. The following outcomes were assessed: systolic blood pressure (SBP), diastolic blood pressure (DBP), urinary albumin-to-creatinine ratio (UACR), 24-h urinary protein, serum creatinine, estimated glomerular filtration rate (eGFR), serum potassium, plasma renin activity, plasma aldosterone, hemoglobin A1c (HbA1c) and the incidence of hyperkalemia. Data were analyzed using RevMan 5.2. For continuous data, mean difference (MD) and 95% confidence interval (CI) were calculated. For dichotomous data, risk ratio (RR) and 95% CI were calculated. When heterogeneity was absent, meta-analysis was performed using a fixed-effects model. Otherwise, a random-effects model was used. Results: A total of 16 studies involving 905 patients were included. The meta-analysis showed that combined MRA with ARB/ACEI for DN patients reduce SBP [MD -1.21, 95% CI (-1.95, -0.47)], 24-h urinary protein [MD -0.33, 95% CI (-0.59, -0.08)], and UACR [MD -0.31, 95% CI (-0.56, -0.05)]. Compared with the control group, combination treatment demonstrated higher serum potassium level [MD 0.26, 95% CI (0.16, 0.35)], plasma renin activity [MD 0.52, 95% CI (0.21, 0.84)], plasma aldosterone [MD 0.59, 95% CI (0.39, 0.79)], HbA1c [MD 0.21, 95% CI (0.11, 0.32)] and the incidence of hyperkalemia [RR 3.89, 95% CI (2.20, 6.88)]. No statistical differences were observed for DBP, serum creatinine and eGFR. Conclusions: For patients with DN, combined therapy could further reduce albuminuria and blood pressure (BP), and inhibit plasma renin and aldosterone without decreasing renal function. A higher risk of hyperkalemia must be taken into consideration.